Tesamorelin 5 Days On 2 Days Off Protocol

Tesamorelin was developed by Theratechnologies and approved by the FDA in 2010 under the brand name Egrifta. It was the first and remains the only GHRH analog approved as a pharmaceutical drug for reducing excess abdominal fat. The approval was specifically for HIV-associated lipodystrophy, a condition where antiretroviral therapy causes abnormal fat accumulation, particularly visceral fat around the organs. The drug is a synthetic analog of human growth hormone releasing hormone, modified to be more stable and resistant to enzymatic breakdown. Natural GHRH has a half-life of minutes. Tesamorelin lasts long enough to produce a sustained GH pulse when injected. Outside of the HIV lipodystrophy indication, tesamorelin has been studied for general visceral fat reduction in non-HIV populations. Research published in the New England Journal of Medicine showed meaningful reductions in visceral adipose tissue in overweight adults. This off-label interest brought tesamorelin into the broader peptide and wellness space.

The 5 days on, 2 days off cycling protocol exists because of how the pituitary gland responds to repeated GHRH stimulation. When you stimulate the pituitary with the same signal every day, it can become desensitized, meaning it releases less GH over time in response to the same dose. Taking two days off per week allows the pituitary receptors to reset and maintain their sensitivity. This is a common pattern with secretagogues. The pituitary is designed to respond to pulses of GHRH, not constant stimulation. A 5/2 cycle mimics a more natural pattern of stimulation and rest. It also gives the body two days per week to operate on its own GH production without external support, which some practitioners believe is better for long-term pituitary health. The standard clinical protocol for tesamorelin uses daily injection, but that is for the HIV lipodystrophy population where the goal is maximum visceral fat reduction. For general wellness and longevity use, the 5/2 cycle balances effectiveness with a more conservative approach to pituitary stimulation. Some users do run tesamorelin daily for periods of time, especially during an initial loading phase. But the 5/2 protocol is the most commonly recommended cycling pattern in the peptide community and aligns with how most GHRH and GHRP peptides are cycled.

Tesamorelin binds to GHRH receptors on the anterior pituitary gland and stimulates the release of stored growth hormone. This is a direct mechanism, not an indirect one like ghrelin mimetics. The GH pulse that results is larger and more sustained than what you get from GHRP peptides alone. The released GH stimulates the liver to produce IGF-1, which mediates most of GH's effects on tissue. IGF-1 promotes protein synthesis, cell growth, and fat metabolism. For visceral fat specifically, GH has a direct lipolytic effect on visceral adipose tissue, breaking down the deep belly fat that surrounds internal organs. Visceral fat is metabolically active and produces inflammatory cytokines. Reducing it improves insulin sensitivity, lowers cardiovascular risk markers, and reduces systemic inflammation. This is why visceral fat reduction is considered more valuable than subcutaneous fat loss from a health perspective. Tesamorelin also has effects on lipid metabolism. Studies show reductions in triglycerides and improvements in the total cholesterol to HDL ratio. These effects are secondary to the visceral fat reduction but contribute to the overall metabolic benefit.

The primary result of tesamorelin is measurable visceral fat reduction. Clinical trials showed an average 15 to 20 percent reduction in visceral adipose tissue over 26 weeks of daily use. With the 5/2 protocol, results may be somewhat slower but still meaningful over a longer timeframe. Users report a flatter abdomen, reduced waist circumference, and less of the hard belly feeling that comes with visceral fat accumulation. The change is gradual and compounds over months. Unlike crash diets that can cause rapid but unsustainable fat loss, tesamorelin produces steady changes that tend to persist as long as lifestyle factors are maintained. NAFLD, or non-alcoholic fatty liver disease, is another area where tesamorelin shows promise. Since visceral fat and liver fat are connected through shared metabolic pathways, reducing visceral fat often improves liver fat as well. Some users start tesamorelin specifically for liver health support. IGF-1 levels increase on tesamorelin, which brings secondary benefits like improved sleep, better skin quality, faster recovery, and enhanced muscle protein synthesis. These are similar to other GH-boosting peptides, but tesamorelin is specifically dosed and studied for the visceral fat application.

A user on r/Peptides shared: “I started tesamorelin for the belly fat that would not budge despite diet and exercise. I am 48 and carry most of my fat viscerally, the hard beer belly type. On the 5/2 protocol at 2 mg daily, I noticed my belt fitting looser around week 6. By month 4 I had lost 3 inches off my waist. My fasting glucose also dropped from 105 to 92, which my doctor was happy about.“ Another user on r/Peptides noted: “The reconstitution was a learning curve, but once I got that figured out the protocol was simple. Inject before bed, 5 nights a week, skip weekends. Sleep improved within the first week, that was the earliest change. The body fat reduction was slower, maybe 8 weeks before I could see it in the mirror. Blood work at 3 months showed my IGF-1 went from 130 to 195.“ Most users describe the experience as uneventful day to day. The changes accumulate quietly and become apparent when you look back at where you started.

• Reduction in visceral belly fat over 3 to 6 months
• Flatter abdomen and reduced waist circumference
• Improved insulin sensitivity and fasting glucose levels
• Better lipid panel, including lower triglycerides
• Deeper sleep and improved sleep quality
• Measurable IGF-1 increase confirmed by blood work
• Potential improvement in liver fat and NAFLD markers
• Enhanced exercise recovery and general wellbeing

Ipamorelin or CJC-1295 without DAC can be added to amplify the GH pulse. Tesamorelin works through the GHRH pathway, and adding a GHRP like ipamorelin stimulates GH release through a second mechanism. This dual-pathway approach produces a larger GH response than tesamorelin alone. BPC-157 is a common addition for gut health and tissue repair. There are no known interactions between BPC-157 and tesamorelin, and they address different goals. AOD-9604 can be stacked for additional fat mobilization. Since tesamorelin targets visceral fat specifically and AOD-9604 targets fat metabolism more broadly, they can work together for a more complete fat loss approach. Some users add metformin or berberine alongside tesamorelin for enhanced insulin sensitivity support. This is a more advanced protocol and should involve blood work monitoring.